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Abstract 
Hypoplastic left heart syndrome (HLHS) is a serious congenital cardiovascular malformation 
resulting in hypoplasia or atresia of the left ventricle, ascending aorta, aortic and mitral 
valves.  Diminished flow through the left side of the heart is clearly a key contributor to the 
condition, but any myocardial susceptibility component is as yet undefined. Using recent 
advances in the field of induced pluripotent stem cells (iPSC), we have been able to generate 
an iPSC model of HLHS malformation and characterise the properties of cardiac myocytes 
(CM) differentiated from these and control-iPSC lines. Differentiation of HLHS-iPSC to 
cardiac lineages revealed changes in the expression of key cardiac markers and a lower 
ability to give rise to beating clusters when compared to control-iPSC and human embryonic 
stem cells (hESC). HLHS-iPSC derived CM show a lower level of myofibrillar organisation, 
persistence of an fetal gene expression pattern, changes in commitment to ventricular versus 
atrial lineages and display different calcium transient patterns and electrophysiological 
responses to caffeine and beta-adrenergic antagonists when compared to hESC- and control-
iPSC derived CM, suggesting that alternative mechanisms to release calcium from 
intracellular stores such as the inositol triphosphate receptor may exist in HLHS in addition to 
the ryanodine receptor thought to function in control-iPSC derived CM.  Together our 
findings demonstrate that CM derived from an HLHS patient demonstrate a number of 
marker expression and functional differences to hESC/control iPSC derived CM, thus 
providing some evidence that cardiomyocyte-specific factors may influence the risk of 
HLHS. 
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Introduction 
 
Hypoplastic left heart syndrome (HLHS) is characterised by underdevelopment of the 
left-sided cardiac structures, variably including hypoplasia or atresia of the left ventricle, 
ascending aorta, and aortic and mitral valves. HLHS is the commonest cause of heart 
transplantation in infancy and is the cardiovascular malformation most frequently resulting in 
childhood death (without surgical intervention, HLHS is invariably fatal). There is a 
substantial familial predisposition to HLHS 
1-3
, though it is not usually a Mendelian condition 
and first degree relatives of probands with HLHS have a high incidence (11%, versus 1-2% in 
the general population) of bicuspid aortic valve. Despite this, only a minority of neonates 
with severe obstruction of left ventricular outflow have HLHS.   Diminished flow through the 
left side of the heart 
1,2
 and disruption of genetic networks specific to left ventricular chamber 
development 
4-7
 have been suggested to cause HLHS.  In particular it has been hypothesised 
that disruption of genetic networks specific to the left ventricular chamber, which depend on 
the differential expression of such genes as Tbx5 and Lrx1, is also contributory to the 
pathogenesis of the condition and loss-of-function mutations in the gene HAND1, which is 
expressed in left-sided cardiac structures including the LV myocardium, are present in a 
proportion of patients with HLHS.  One report has noted that HLHS patient cardiac myocytes 
show inappropriate expression of PECAM-1 (CD31) and indications that the HLHS left 
ventricle has a gene expression pattern reminiscent of a heart failure or fetal gene expression 
pattern
8
. As yet however, there is relatively little evidence in favour of the role of CM-
specific factors in HLHS risk. We have derived iPSC lines from one HLHS patient who 
demonstrated mild facial dysmorphism, bilateral hip dislocation, hypoplastic fingernails, mild 
microcephaly, aortic atresia and mitral atresia who subsequently died at 10 days of age. CM 
differentiated from these lines show substantial differences to those obtained from hESC 
9
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and control-iPSC lines derived from unaffected neonatal human dermal fibroblast (NHDF), 
supporting the hypothesis that patient specific myocardial developmental factors make a 
substantial contribution to the development of HLHS. 
 
Materials and methods 
Cell source: Dermal fibroblasts derived from the skin biopsy of one HLHS patient 
(GM12601) were obtained from the Coriell Institute for Medical Research. The patient was 
clinically diagnosed with hypoplastic left heart syndrome characterised by aortic and mitral 
atresia. Associated malformations included mild facial dysmorphism, bilateral hip 
dislocation, hypoplastic fingernails, and mild microcephaly.  The patient died ten days after 
birth. 
 
Derivation, culture and characterisation of human iPSC lines was performed using a 
polycistronic lentiviral system (Allele Biotech) 
10
. For more details refer to the 
Supplementary Annex. 
 
Cardiac differentiation of human ESC/iPSC lines and characterisation of cardiac 
progenitors was carried out as described in 
11
 with full details presented in the 
Supplementary Annex.  
 
DNA fingerprinting and karyotype analysis were performed as described in 
12 
(for more 
details refer to Supplementary Annex).  
 
Flow cytometric analysis. Human iPSC were cultured under feeder free conditions (matrigel 
and murine embryonic feeder cells conditioned media) for two passages. Single cell 
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dissociation was achieved by adding accutase for five minutes and incubating at room 
temperature.  200,000-500,000 single cells were resuspended in PBS supplemented with 5% 
FCS and added to a well of a 96-well plate (U shaped). The plate was spun at 200g for five 
minutes at 4°C and the supernatant was discarded by flicking the whole plate with adherent 
cells remaining attached to the bottom. Isotype control or conjugated TRA-1-60 (Millipore 
and NANOG (Cell Signaling Technologies) were added at dilution of 1:50 followed by 
incubation on ice for one hour. Cells were rinsed three times with PBS as before and finally 
resuspended in 0.5 ml of PBS + 5% FCS for FACS analysis using an LSRII analyser (BD 
Biosciences). At least 10,000 cells were analysed for each experiment. A similar procedure 
was followed for the NANOG staining with the exception of one additional step of cell 
permeabilisation and fixation with 2% PFA at 37°C for 10 minutes prior to antibody addition. 
 
 
Transmission electron microscopy, Measurement of Cytosolic [Ca
2+
] and Multi-
electrode array recordings were used to further characterise hESC/iPSC derived CM (for 
full details, refer to Supplementary Annex). 
 
DNA sequencing of cardiac specific genes. Coding regions of NKX2.5, HAND1 and 
HAND2 genes, including exon-intron boundaries were amplified by polymerase chain 
reaction (PCR) from genomic DNA of control and HLHS patient derived fibroblasts and 
iPSC and sequenced (for full details, refer to Supplementary Annex). 
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Results and Discussion 
Two iPSC clones were derived from one HLHS patient and one unaffected control.  
Both HLHS clones behaved very similarly so the data are presented as the average of the two 
clones wherever possible. iPSC derivation efficiency was lower for HLHS (0.0002%) than 
control-iPSC (0.3%). A recent paper that was published while this manuscript was under 
review has shown the prevalence of a senescent phenotype in HLHS derived CM and 
endothelial cells 
13
. If this was to be true for fibroblasts derived from HLHS patients, it could 
explain the low efficiency of iPSC derivation as suggested by Marion et al. 
14
 , 
All resulting iPSC were highly similar to hESC (H9) (Figure 1A). Exogenous 
transgenes were silenced in all pluripotent iPSC lines (Figure 1B). All HLHS iPSC lines 
were karyotypically normal (Figure 1C) and isogenic with the parent fibroblasts (Suppl. 
Figure 1). Flow cytometric analysis for NANOG and TRA-1-60 expression (Figure 1D) was 
performed in all iPSC and only the iPSC lines that showed expression of those markers in 
more than 90% of the cells were taken forward for further analysis. Pluripotency was further 
confirmed by multilineage differentiation as embryoid bodies (EBs) followed by expansion in 
monolayer culture. Immunohistochemical staining for β-III-tubulin, α-fetoprotein and CD31 
indicated the presence of differentiated cell types derived from ectoderm, endoderm and 
mesoderm in all samples (Figure 2A). Sub-cutaneous injection of HLHS- and control-iPSC 
into immunocompromised NOD/SCID mice gave rise to teratomas containing tissues derived 
from all three embryonic germ layers (Figure 2B). These results demonstrated that fully 
reprogrammed iPSC can be derived from HLHS patients.   
We differentiated hESC, HLHS- and control-iPSC lines into CM using protocols 
published by Keller’s group 
11
. We were particularly interested in investigating the 
differences between HLHS and patient CM as they emerged during human embryonic 
development and for this reason we focused our studies on the first 21 days of iPSC and ESC 
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differentiation which has been reported by a large number of studies to be sufficient for 
cardiac commitment and generation of contracting CM. Contracting clusters containing cells 
expressing cardiac markers such as α-actinin, cardiac troponin (cTnT) and the early cardiac 
development transcription factor HAND1
15
, could be readily detected by 
immunohistochemistry from day 10 of differentiation (Figure 3A). Quantitative RT-PCR 
analysis during differentiation suggested that HLHS-iPSC, control-iPSC and hESC down-
regulated pluripotency markers as shown by SOX2 (Figure 3B) and NANOG expression 
(Suppl. Figure 2A) and formed mesoderm indicated by expression of BRACHYURY (Figure 
3B). We noticed a lower expression of a key marker of cardiac mesoderm, MESP1 at 
differentiation day 10 (Figure 3B) in addition to delayed and persistent expression of the 
cardiac progenitor marker, GATA4 and reduced expression of a more mature CM marker, 
cardiac troponin (cTnT) at days 14 and 21 of differentiation for the HLHS sample. Although 
ANOVA two factor analysis indicated no significant differences between H9, NHDF and 
HLHS samples during the differentiation time course for the expression of above mentioned 
cardiac markers, t- test analysis performed at specific and key time points indicated that the 
changes observed between HLHS and each of the two controls (NHDF and H9) were 
significant (p < .05).  Quantitative RT-PCR analysis also indicates higher than expected 
expression of PECAM-1 (CD31) and the embryonic atrial myosin essential light chain (ALC-
1) in HLHS-derived CM compared to hESC and control iPSC lines (Suppl. Figure 3) which 
supports the observations made by Bohlmeyer et al
8
 about persistence of fetal gene 
expression in of the heart of HLHS patients.   It is interesting to note higher expression of 
MYH6 (fast isoform of the cardiac myosin heavy chain preferentially expressed in developing 
atria, Figure 3B) and decreased expression of MYH7 (myosin heavy chain beta 
predominantly expressed in ventricles; Suppl. Figure 2B). This was corroborated by flow 
cytometric analysis of beating clusters, which show reduced cTnT expression and CX43 
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(found mainly in ventricular myocardium) in parallel to increased expression of CX40 
(enriched in atrial CM) and ANP (atrial natriuretic peptide; Figure 3C).   
A number of publications to date have suggested variations between iPSC clones 
derived from the same patients as well as iPSC lines derived from different patients in the 
ability to give rise to cardiomyocytes, thus necessitating inclusion of iPSC lines from 
multiple HLHS patients. This is difficult for congenital diseases such as HLHS where 
improvement in fetal imagining have actually led to decreased numbers of babies with HLHS. 
During this study, we have not observed significant differences between iPSC clones derived 
either from the unaffected control or the HLHS patients. Furthermore, we have not observed 
significant differences between the H9 human ESC lines and the unaffected control, which 
lead us to speculate that differences observed between control and HLHS patient are due to 
the HLHS phenotype rather than intra and inter line variability. It is also encouraging to 
notice, that another group reported similar differences in gene expression profile and 
ventricular/atrial commitment of cardiomyocytes using independently derived iPSC clones 
from two other HLHS patients (Bossman et al. ISSCR poster T-3147, Boston 2013). Together 
these findings suggest that HLHS may be characterized by impaired differentiation of cardiac 
lineages affecting multiple steps such as cardiac mesoderm formation, maturation of cardiac 
progenitors to fully mature CM and commitment to atrial or ventricular phenotype.  
Greatly reduced expression of CX43 has been observed in HLHS cardiac myocytes by 
other workers.
16
 CX43 functions in the electromechanical transduction and signaling between 
cardiomyocytes to facilitate maturation, alignment, and proliferation during development of 
the myocardium. The reduced CX43 expression shown by HLHS iPSC derived CM supports 
the possibility that myocardial development may be compromised by failure to correctly align 
cardiac myocytes.  Alternatively, the higher expression of CX40 may indicate that greater 
numbers of ventricular conduction system (VCS) cardiomyocytes arise during differentiation 
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of HLHS iPSC.  CX40 is a known marker of this latter cell type
17 -19 
and our observed data 
support the possibility of increased numbers of VCS cardiomyocytes. Sequencing of coding 
regions of NKX2.5, HAND1 and HAND2 revealed no mutations in HLHS patient sample, 
excluding those genes as causal factors (data not shown). 
Transmission electron microscopy (TEM) of hESC and iPSC derived CM revealed 
that most CM are mononucleated; however, while densely packed parallel myofibrils 
organized into apparently mature sarcomeres with Z-band formation were observed for 
hESC- and control-iPSC derived CM (Figure 4A: a and e), a more random arrangement of 
myofibrils was observed in HLHS-iPSC derived CM despite the presence of abundant Z-
bands (Figure 4A: i). Moreover CM from hESC and control-iPSC show conspicuous rough 
endoplasmic reticulum and sarcoplasmic reticulum (Figure 4A: b, c, f, g indicated by 
arrows), but these structures are less apparent in HLHS-iPSC derived CM (Figure 4A: j, k).  
 Numbers and beating rates of contractile areas from HLHS-iPSC EBs are 
substantially lower than those from hESC or control-iPSC (Figures 4B and C) prompting 
detailed examination of CM calcium release characteristics. Spontaneous rhythmic calcium 
transients were detected in H9, unaffected control and HLHS-iPSC derived CM (Suppl. 
Figure 4A). Interestingly, HLHS-iPSC derived CM show an accelerated rate of Ca
2+
 
transient decay compared to control-iPSC derived CM (Suppl. Figure 4B). In fully 
differentiated cardiac muscle, the sarcoplasmic reticulum is the major source of Ca
2+
 required 
for contraction 
20,21
. HLHS-iPSC derived CM generate calcium transients in the presence of 
caffeine whereas control-iPSC derived CM do not (Suppl. Figure 4C) implying ryanodine 
receptor dysfunction in HLHS-iPSC derived CM. The contractile areas are still able to beat 
so an alternative source of calcium such as the inositol triphosphate system may be operative. 
This is indicated by upregulation of IP3R expression in HLHS derived CM compared to 
control CM (Suppl. Figure 5). Multi-electrode array studies of contracting areas also support 
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sarcoplasmic reticulum dysfunction.  Treatment of CM with the β1/β2 adrenergic receptor 
agonist isoproterenol normally increases the contraction frequency by enhancing Ca
2+
 
ATPase activity in the sarcoplasmic reticulum 
22
; however, the beat frequency of HLHS-iPSC 
derived CM increases only by 9% after isoproterenol treatment compared to 66% for hESC 
derived CM (Suppl. Figure 6). Therefore, it is possible that for HLHS, inositol triphosphate 
plays an important role in generating calcium transients.  This is also an indicator of 
immature cardiac differentiation.  Set against these data is the observation that control-iPSC 
derived CM only demonstrate 20% increase in beat frequency; however the inability of 
HLHS-iPSC derived CM to increase their beat frequency is significant. 
Summary: We have presented data describing the derivation of two iPSC lines from an 
HLHS patient and demonstrated that CM derived from these lines show developmental 
and/or functional defects that could compromise their ability to contribute to cardiogenesis in 
vivo.  Our observations of such intrinsic cellular defects correlate with the findings of other 
groups such as the possibility that gene expression programs more typical of a fetal cardiac 
phenotype may persist in HLHS-iPSC-derived CM.  Further studies are needed to determine 
if these defects are causative of HLHS not least of which will be the need to derive more 
patient specific iPSC to address questions of patient genetic background outside the factors 
responsible for the HLHS phenotype. Differentiation of HLHS-iPSC to CM is a valuable tool 
in this investigation since it permits examination not only the more mature stages of CM 
development but also allows us to access several of the cardiac mesoderm cell types that 
precede CM formation which is not possible from the HLHS patient tissues alone.  
Comparison of the transcriptomic and functional parameters of such cells will be a useful 
mechanism through which we may identify candidate genes whose mutations may contribute 
to the HLHS phenotype. 
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Figure legends  
 
Figure 1. Molecular characterisation of human iPSC lines derived from HLHS patient and 
unaffected control.  (A) Staining of NHDF derived control- and HLHS-iPSC lines and H9 
hESC with pluripotency markers and alkaline phosphatase (AP). DAPI staining of nuclei is 
shown in blue. This is a representative example of at least three independent experiments. 
Scale bar, 100µm; (B) quantitative RT-PCR analysis for the expression of total and 
endogenous c-MYC and SOX2 relative to GAPDH with H9 as calibrator (set to 1). Data is 
presented as mean +/- SEM, n=3; (C) A representative example of karyotypic analysis of 
HLHS-iPSC1 showing a normal 46 XY karyotype; (D) Flow cytometric analysis for 
expression of TRA-1-60. The red line represents the cell population stained with the isotype 
control and the green line the control sample stained with TRA-1-60 antibody. This is a 
representative example of at least three independent replicates with the NHDF1 iPSC clone. 
 
 
Figure 2.   (A)  In vitro and in vivo differentiation capacity of hESC, NHDF derived 
control- and HLHS-iPSC lines. In vitro differentiation capacity to all three germ layers 
demonstrated by immunocytochemical staining with an anti-AFP antibody (endoderm), anti-
CD31 antibody (mesoderm) and anti-βIII-Tubulin antibody TUJ1 (ectoderm). DAPI staining 
of nuclei is shown in blue. This is a representative example of at least three independent 
experiments. Scale bar, 100µm; (B) In vivo differentiation of hESC line H9 (upper panel), 
NHDF1-iPSC (middle panel) and HLHS1-iPSC (lower panel). All three pluripotent stem cell 
lines produced teratomas containing structures representative of each germ layer, notably 
neuroepithelium (a,d and g: ectoderm), kidney/gut wall  (b,e/h respectively; both endoderm) 
and cartilage (c, f and i: mesoderm).Histological staining: Masson’s Trichrome for  iPSC-
HLHS mesoderm and Weigert’s stain for all other sections. Scale bars: NHDF1-iPSC and 
iPSC-HLHS 150 µm, the rest are 75 µm.  
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Figure 3.   Differentiation of NHDF derived control-iPSC, HLHS-iPSC and H9 hESC to 
CM in vitro. (A) Staining with cardiac markers α-actinin, cTnT and HAND1. Please note a 
mixed expression pattern of HAND1 in nucleoli and nucleus as previously described in 
literature. DAPI staining of nuclei is shown in blue. This is a representative example of at 
least three independent experiments. Scale bar, 100µm; (B) Quantitative RT-PCR analysis 
showing changes in cardiac marker expression during the differentiation of iPSC and hESC 
lines. Human embryonic heart cDNA was used as calibrator for MESP1, GATA4, cTnT and 
MYH6 whilst hESC cDNA was used as calibrator for SOX2 and BRACHYURY.  The 
calibrator value was set to the value of 1 and all other data was calculated with respect to that. 
Data are presented as mean +/- SEM, n=6. * indicates significant differences in expression 
between HLHS and each of the controls: H9 and NHDF as revealed by t-test at the particular 
time point of differentiation; (C) Flow cytometry data analysis of cardiac markers 
demonstrating changes in expression profiles of HLHS-iPSC derived CM when compared to 
control derived cells at day 21 of differentiation. Data are presented as mean +/- SEM, n=6. 
Anova single factor analysis followed by Bonferroni post hoc test indicated significant 
differences between HLHS and each of the controls (H9 and NHDF) but no differences 
between NHDF and H9. For simplicity, only *p< .05 is indicated for the comparison between 
NHDF and HLHS iPSC lines. 
 
Figure 4.  (A) Transmission electron microscopy analysis of CM derived from control- 
and HLHS-iPSC derived cells and H9 hESC line at day 21 of differentiation. Left 
column shows highly organized, densely packed, paralleled myofilaments in H9 and NHD1-
CM with obvious z-bands (a and e); Less organised sarcomeres (indicated by black arrows, 
panel i) are observed in the HLHS-derived CM. N= nuclei, ER – endoplasmic reticulum, M – 
mitochondria, L – lipids, z- z bands. This is a representative example of at least three 
independent experiments; (B) Analysis of beating EBs derived from H9, control iPSC 
(NHDF) and HLHS patient specific iPSC lines.  Schematic presentation of percentage of 
beating EBs throughout differentiation window (300 EBs were analysed for each time point). 
Data are presented as mean +/- SEM, n=6. Anova two factor with replication followed by 
Bonferroni post hoc test indicated significant differences between HLHS and NHDF 
(p=0.006) and HLHS and H9 (p=0.005); (C) Analysis of beating rate at day 21 of 
differentiation time course (100 EBs were analysed in each experiment, n=6).  
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Suppl. Figure 1. Representative DNA fingerprinting analysis showing that HLHS-iPSC 
1 and 2 are genetically identical to the patient fibroblast. 
 
Suppl. Figure 2. Quantitative RT-PCR analysis for the expression of (A) NANOG 
during iPSC and hESC differentiation timecourse and (B) MYH7 at day 21 of 
differentiation. Data are presented as mean +/- SEM, n=6. Calibrator sample for (A) 
undifferentiated hESC cDNA and for (B) Human embryonic heart cDNA. (B) Anova single 
factor analysis followed by Bonferroni post hoc test indicated significant differences between 
HLHS and each of the controls (H9 and NHDF) but no differences between NHDF and H9. 
For simplicity, only *p< .05 is indicated for the comparison between NHDF and HLHS iPSC 
lines. 
 
 
Suppl. Figure 3. Quantitative RT-PCR analysis for the expression of CD31 and ALC-1 
at day 21 of differentiation. Data are presented as mean +/- SEM, n=6. Calibrator sample: 
human embryonic heart cDNA. T-test was used to analyse the significance between NHDF 
and HLHS for each of the genes analysed. 
 
Suppl. Figure 4. Characterisation of spontaneous Ca
2+
 oscillations from embryoid body 
derived CM. (A) Confocal line scan images showing changes in intracellular Ca
2+
 with each 
contraction; (B) Data showing mean ± SEM summarising Ca
2+
 transient amplitude (upper 
panel, pseudo-ratio units), the period of spontaneous Ca
2+
 oscillations (middle panel) and 
time taken for the Ca
2+
 transient to decay by 90%;  (C) Spontaneous Ca2+ changes presented 
as pseudo-ratio (F/Frest) units obtained under baseline conditions (left hand panels), following 
caffeine mediated inhibition of ryanodine receptor mediated Ca
2+
 release from internal stores 
(middle panels) and wash-off of caffeine (DMEM, right panels). Note that in the NHDF- 
control-iPSC EB, caffeine immediately and permanently prevented all spontaneous Ca
2+
 
oscillations (upper panels) whereas in the HLHS-iPSC EB (lower panels) rhythmic 
spontaneous Ca
2+
 oscillations, at a reduced frequency, were still observed in the presence of 
caffeine suggestive of the presence of alternative Ca
2+
 sources in the HLHS-iPSC derived 
CM. These are representative examples from at least three independent experiments 
performed in H9 and NHDF1- and HLHS1-iPSC derived beating EBS. 
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Suppl. Figure 5. Quantitative RT-PCR analysis for the expression of IP3R at day 21 of 
differentiation. Data are presented as mean +/- SEM, n=6. Calibrator sample: hESC cDNA 
day 21. Anova single factor analysis followed by Bonferroni post hoc test indicated 
significant differences between HLHS and each of the controls (H9 and NHDF) but no 
differences between NHDF and H9.  
 
 
Suppl. Figure 6.  Field potential recordings from H9, NHDF control-iPSC and HLHS-
iPSC spontaneously beating EBs at day 21 of differentiation and their responses to an 
adrenergic agonist (isoproterenol). Panels A and B respectively represent responses before 
and after isoproterenol administration. Recordings were performed for three biological 
replicates. These are representative examples from at least three independent experiments 
performed in H9 and NHDF1- and HLHS1-iPSC derived beating EBS. 
 
 
Suppl. Table 1.  Summary of all the oligonucleotides used for RT-PCR.  
 
 
Suppl. Table 2.  Summary of all the oligonucleotides used for mutation screening analysis.  
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IP3R Forward GAAGAAACTACAGCACGCTG  
IP3R Reverse TTCTCCAGTAAAGCAGGTAA 
BRACHYURY  Forward TGA GGA GAT TAC AGC CCT TAA A 
BRACHYURY  Reverse GGT TCC TTA GAG CTG GGT AC 
GATA4  Forward CCC TAC CCA GCC TAC ATG G 
GATA4  Reverse ACA TAT CGA GAT TGG GGT GTC T 
ISL-1  Forward TTG TAC GGG ATC AAA TGC GCC AAG 
ISL-1  Reverse AGG CCA CAC AGC GGA AAC A 
cTNT  Forward TTC ACC AAA GAT CTG CTC CTC GCT 
cTNT  Reverse TTA TTA CTG GTG TGG AGT GGG TGT GG 
MYH6  Forward TCAGCTGGAGGCCAAAGTAAAGGA 
MYH6  Reverse TTCTTGAGCTCTGAGCACTCGTCT 
MYH7  Forward TCGTGCCTGATGACAAACAGGAGT 
MYH7  Reverse ATACTCGGTCTCGGCAGTGACTTT 
NANOG  Forward GCG GAC TGT GTT CTC TCA GGC 
NANOG  Reverse TTC CAG ATG CGT TCA CCA GAT AG 
SOX2  endo Forward GGCGCTTTGCAGGAAGTTTG 
SOX2  endo Reverse GCAAGAAGCCTCTCCTTGAA 
SOX2  total Forward AACCCCAAGATGCACAACTC 
SOX2  total Reverse TCTCCGTCTCCGACAAAAGT 
c-MYC  endo Foward GAA CTT ACA ATC TGC GAG CC 
c-MYC  endo Reverse AGT CGA GGT CAT AGT TCC TG 
c-MYC  total Forward TCAAGAGGCGAACACACAAC 
c-MYC  total Reverse GGCCTTTTCATTGTTTTCCA 
CD31 Forward TCAAATGATCCTGCGGTATTC 
CD31 Reverse CCACCACCTTACTTGACAGGA 
ALC-1 Forward GGTAAGAGCGTAGGTGAATCCC 
ALC-1 Reverse TTACTGCGGCTTCATACTGAGG 
VLC-1 Forward AGATCACCTACGGGCAGTGT 
VLC-1 Reverse AGTCCATCATCTTGGTATTGAGC 
 
Supplementary Table 1. Summary of oligonucleotides used in the qRT-PCR analysis. 
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Suppl. Table 2. The sequence of oligonucleotides used for the mutation screening analysis. 
 
 Gene  Exon Primers (5'→3') Length (bp) Annealing
temp(
o
C) 
HAND1 799 5'-TGA GCG TAA AAC CTG GGA TAG -3' 
5'- GAA GTA GGG CCT TTC CTG ATG  -3' 
470 53.2 
HAND1 799 5'- GCA TGG AGC GGC GTT AAT AG  -3' 
5'- GCG CAG AGT CTT GAT CTT GG -3' 
463 58.4 
HAND1 799 5'- GGC CCT ACT TCC AGA GCT G -3' 
5'- CTA CCT GCA TGG CCT GAG -3' 
499 58.4 
HAND1 938 5'- TCA TCT TAC CCC ATG CCG G -3' 
5'- GTG CGT CTT TGA GCC CTT G  -3' 
505 61.8 
HAND1 938 5'- CAC ACT TGG ATC GCA CGT G  -3' 
5'- GG CAG CCT TTC ATC TTC CTG -3' 
341 61.8 
HAND1 938 5'- TTG TCC CTC CAT ATG ATC CG -3' 
5'- GAA CAG AGG CTT TCC ACC TAG -3' 
526 53.2 
HAND2 61 5'-GTT TAT AGC ATG GGG AGG AG -3' 
5'- AGA AGT GCC TTA AGG CCC AG -3' 
321 51.7 
HAND2 107 5'-TCC TGG AAC CCA TCC TCA G    -3' 
5'- GCA AGT GTC TGT AAA CAC AG  -3' 
322 53.2 
HAND2 1288 5'- GGT AGC GCT AAC CTT GGT AG  -3' 
5'- AC GGG ATC CCT TAC CAC AC    -3' 
542 53.2 
HAND2 1288 5'- CTG AGG ACT CCT TGC ATT TG    -3' 
5'-ACT CTT TTG AGG TAT CAG CC  -3' 
609 53.2 
HAND2 1288 5'-GAT GTT TCC AAC AGC CAC TTG -3' 
5'- GCC TCA AGA AAT GGC TTC TG -3' 
519 58.4 
HAND2 1288 5'- GAA CGC TGA GTA GTC TCT AG  -3' 
5'- CTC TTT AAA TCC GTG GTC TTG  -3' 
417 58.4 
HAND2 2150 5'-TCC AAT TGG GCT GAG AAA TG   -3' 
5'- AAC TCA GGG CTC AGT CTC TG  -3' 
421 55.5 
HAND2 2150 5'TAA GTC TCG AAG AAG CCC TTG-   -3' 
5'-AGC TCT ATC CTG CAC CAC TG   -3' 
392 61.8 
NKX2.5 563 5'- CTT CCA AAT GCG TCG TGG C  -3' 
5'- TGC TGC TGT TCC AGG TTT AG  -3' 
422 53.2 
NKX2.5 563 5'- CAC GCC CTT CTC AGT CAA AG  -3' 
5'- CAC CAG GCA TCT TAC ATT CTG   -3' 
449 61.8 
NKX2.5 1397 5'-AGC CTG AAA TT TTAAGTCACCG   -3' 
5'- ACTT GT AGC GCC GGT TCT G   -3' 
510 58.4 
NKX2.5 1397 5'-CAG GTC TAT GAG CTG GAG C   -3' 
5'-TCG GAT ACC ATG CAG CGT G    -3' 
522 55.5 
NKX2.5 1397 5'- CTA CGG TTA TAA CGC CTA CC   -3' 
5'- AAA CTC TCC CGT GCG CAA G  -3' 
412 58.4 
NKX2.5 1397 5'-ATT CCG CAG AGC AAC TCG G    -3' 
5'-TGC CTG AGA TCT GAG ACC AG    -3' 
599 58.4 
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Cell culture and lentiviral transductions 
Dermal fibroblasts derived from the skin biopsy of one HLHS patient obtained from 
the Coriell Institute for Medical Research (GM12601) were cultured in tissue culture 
coated flasks (Iwaki T25) in Iscove’s Modified Dulbecco’s Medium, plus 10% fetal 
calf serum (PAA, Somerset, UK), 2 mmol L-glutamine, 0.1 mmol nonessential amino 
acids and 100 units/mL penicillin (all PAA). Induction of pluripotency was performed 
using a polycistronic lentiviral vector encoding OCT4, SOX2, KLF4 and c-MYC under 
the control of an EF1α promoter (Allele biotech, San Diego, USA) as described in our 
previous publication
9
. Briefly, fibroblasts were infected with lentiviral particles  
(MOI=2) with addition of 6µg/ml polybrene in Iscove’s Modified Dulbecco’s 
Medium, plus 10% fetal calf serum (PAA), 2 mmol L-glutamine, 0.1 mmol 
nonessential amino acids, 100 units/mL penicillin (PAA) for 48 hrs. Six days after 
transduction, fibroblasts were disaggregated and plated onto feeder layers of 
mitotically inactivated mouse embryonic fibroblasts in hESC culture medium (KO-
DMEM, 20% Knockout™ Serum Replacement, 0.1 mmol nonessential amino acids, 2 
mmol L-glutamine, 100 units/mL penicillin and 10ng/mL human recombinant bFGF) 
at a density of 8,000 cells per one well of a six well plate. The feeder plates with 
lentiviral vector treated cells were maintained at 37
o
C / 5% CO2 in hESC medium for 
2-3 weeks or until colonies of cells with morphology similar to hESC appeared.  
These were mechanically dissected into several pieces and plated onto fresh feeder 
cells to develop further colonies for characterisation. In this study, we have used the 
hESC line, H9 and the neonatal human dermal fibroblast (NHDF)-derived-iPSC as 
our parallel controls. 
 
Teratoma formation 
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Approximately 5x10
5
 NHDF-derived-iPSC, HLHS-patient-specific iPSC and hESC 
were injected subcutaneously into the right flanks of adult NOD/SCID mice and 
maintained for 6-12 weeks. All cells were co-transplanted with 50µl Matrigel (BD 
Biosciences) to enhance teratoma formation. After 8 weeks, mice were sacrificed, 
teratoma tissues were dissected, fixed in Bouins overnight, processed and sectioned 
according to standard procedures then counterstained with either haematoxylin and 
eosin or Massons trichrome stain. Sections (5-8µm thick) were examined using bright 
field light microscopy and photographed as appropriate. 
 
Quantitative RT-PCR 
Total RNA was isolated using TRIzol Reagent (Invitrogen) at different points during 
the differentiation process. Genomic DNA was removed by treatment with DNaseI 
(Ambion) at 37°C for 30 minutes. Total RNA (1µg) was used for reverse transcription 
using the SuperScript III First strand synthesis system (Invitrogen). Details of the 
panel of differentiation markers, cardiac specific markers and calcium handling 
protein genes are listed in Suppl. Table 1. Quantitative RT-PCR was performed using 
an ABI 7900 with the iQ SYBR Green Supermix (Promega). Data was analysed using 
qBase v1.3.5 and the comparative threshold cycle (Ct) method. In all samples the 
results were normalised to the expression level of the housekeeping gene GAPDH, 
and referenced to hESC and  human embryonic heart cDNA (obtained from Carnegie 
Stage 14) depending on the gene of interest being analysed. 
 
EB formation and cardiac differentiation 
Before EB formation, the iPSC and hESC were cultured in matrigel-coated plates for 
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3 days to deplete the feeder cells (Day -3). On day 0, the colonies were detached and 
separated mechanically in small clusters (around 500-1000 cells/per clump), then 
placed on low attachment plates (Costar) in suspension with differentiation medium 
consisting of StemPro-34 (Invitrogen), supplemented with 10ng/mL 
penicillin/streptomycin, 2mmol L-Glutamine, 1mmol ascorbic acid, and 0.4mmol 
monothioglycerol (MTG) (Sigma). BMP4, Activin A, DKK1, VEGF (R&D systems), 
SB (Tocris) and b-FGF were added at the indicated time points and concentrations for 
each cell lines individually as described in literature methods
10
.  After 7 days in 
suspension culture, the EBs were plated on 0.1% gelatin-coated 12 well culture plates 
at the density of 20 EBs per well and cultured in cardiac medium (changed every 2-3 
days). The number of contracting EBs and contraction rates were measured every 
second day using a Zeiss microscope with a heated stage (37°C). Beating areas were 
usually observed 2 or 3 days after re-plating and reached maximal numbers normally 
by day 20. These areas were cut carefully and used for other characterisation 
experiments. 
 
Immunocytochemical analysis 
Undifferentiated iPSC and hESC were plated on 4 well plates under feeder free 
conditions as described above, whilst single cardiac myocytes were isolated from 
beating areas using Accutase (Invitrogen) digestion for 10 minutes at 37°C followed 
by plating onto 0.1% gelatin coated chambers with cardiac medium for 2 days to 
allow cell attachment. Cells were fixed in 4% paraformaldehyde for 10 minutes at 
room temperature followed by treatment with 0.5% Triton X-100 for 10 minutes. 
Samples were blocked by incubation with 5% BSA for 1 hour at room temperature. 
Primary antibodies used in this study are anti-OCT-4 (1:100, Millipore, Watford, 
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UK), anti-SSEA-4 (1:100,BD Pharmingen), anti-TRA-1-60 (1:100; Millipore), anti-
CD31 (1:100, PECAM1), anti-β-III-Tubulin (TUJ1) (1:100; Covance, New Jersey 
USA), anti-AFP (1:100; Sigma), anti-mouse IgG-FITC conjugated (1:800; Sigma), 
anti-rabbit rhodamine (1:800). The nuclei were counterstained with 10µg/mL Hoechst 
33342 (Life Technologies). The bright field and fluorescent images were obtained 
using a Zeiss microscope and the AxioVision software (Carl Zeiss, Jena, Germany). 
All antibodies were checked for specificity on heart sections from human embryos 
obtained from HDBR (www.hdbr.org). 
Flow cytometry 
The EB (and/or contractile areas) at different time points were collected and digested 
with Accutase for 5-7 minutes to obtain a single cell suspension. Cells were washed 
with PBS and fixed using 4% formaldehyde for 10 minutes followed by 
permeabilization with methanol for 30 minutes.  Samples were incubated with the 
primary antibodies for 1 hour followed by incubation with an appropriate Alexa fluor 
488 conjugated secondary antibody for 30 minutes. DNA staining dye (DAPI) was 
added before analyzing the samples by flow cytometry (FACS Canto (BD 
Biosciences, CA, USA). At least 10,000 events were collected and the data was 
analyzed utilizing FlowJo version 6.4 software. All experiments were performed in 
triplicate. 
DNA fingerprinting 
To confirm that HLHS-patient-specific (HLHS1, HLHS2) and unaffected iPSC 
(NHDF1 and 2) lines were genetically identical to the respective patient dermal 
fibroblasts, DNA fingerprinting was carried out. Total genomic DNA was extracted 
from all five samples and amplified with 15 microsatellite markers: D3S1358, TH01, 
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D21S11, D18S51, Penta-E, D5S818, D13S317, D7S820, D16S539, CSF-1PO, Penta-
D, vWA, D8S1179, TPOX and FGA and analysed on an ABI 377 sequence detector 
using Genotype software (Applied Biosystems, Foster City, CA).  
 
Karyotype analysis of HLHS patient specific and unaffected hiPSC 
Karyotypes were determined by standard G-banding procedure, as described in 
Stojkovic et al 
11
.  
 
Transmission electron microscopy 
Transmission electron microscopy was performed on day 30 contracting EBs fixed 
with 2% glutaraldehyde in 0.1M cacodylate buffer. Post fixation was performed at 
room temperature for 1 hour with 1% osmium and 1.5% postassium ferrocyanide. The 
samples were dehydrated in graded acetone and embedded in epoxy resin at 60°C. 
Half micron sections were stained with 1% toluidine blue and ultra-thin section were 
cut on Leica EM UC7 ultramicrotome and double stained with 1% uranyl acetate and 
lead citrate. Ultrastructual examination was performed with Philips CM 100 TEM at 
100 kV. Digital images were recorded with an AMT40 CCD camera (Deben). 
Measurement of Cytosolic [Ca
2+
] 
Beating clusters were micro-surgically dissected and plated on the gelatine covered 
chamber slide (BD) for cytosolic calcium transient analysis. Briefly, the cells were 
loaded with Fluo3AM (10 µmol) at 37°C for 40 minutes and allowed to de-esterify 
for at least 30 mins at 37
o
C.  Spontaneous calcium transients were recorded using a 
Leica TCS SP2 inverted confocal microscope (excitation 488 nm, emission 510-600 
nm; using an HCX APO L U-V-I  40.0x0.80 W objective). To assess the role of the 
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intracellular Ca
2+
 store, the sarcoplasmic reticular (SR) of beating EBs were 
superfused with caffeine (20 mmol) to discharge the Ca
2+
 store.  Ca
2+
 transients 
amplitude, period and decay kinetics (single exponential function fitted to decay 
phase of Ca
2+
 transients) were calculated using custom VBA routines. 
Multi-electrode array recordings 
To characterize the electrophysiological properties of iPSC derived CM, contracting 
EBs were dissected and plated on gelatin coated multi-electrode arrays (Multichannel 
Systems, Reutlingen, Germany) consisting of 60 titanium nitride electrodes (30 µm 
diameter, 200 µm separation) in a 8x8 configuration without corners. Recordings 
were performed at a sampling rate of 20 kHz. The recorded electrograms were used to 
determine the local field potential (FP) duration (FPD). This parameter was 
previously shown to correlate with the action potential duration and to reflect the local 
QT interval 
12,13
. To assess the responsiveness of cardiac contractility to b-
adrenoceptor stimulation, 20µL of isoproterenol (Sigma) was added directly to the 
recording chamber (2 mL volume). Extracellular recordings were performed for 200 
seconds in control conditions and at 5 minutes after drug application.  
 
DNA sequencing of cardiac specific genes 
Coding regions of NKX2.5, HAND1 and HAND2 genes from HLHS-patient-specific 
fibroblasts and iPSC, including exon-intron boundaries were amplified by polymerase 
chain reaction (PCR) of genomic DNA and sequenced. The sequences of 
oligonucleotides used for this analysis are shown in Suppl. Table 2. PCR was 
undertaken for 5'-UTR and 3'-UTR of exons 799bp and 938bp of HAND1, exons 
563bp and 1397bp of NKX2.5, and exons 61bp, 107bp, 1288bp and 2150bp of 
HAND2. Neonatal human diploid fibroblasts (NHDF) and NHDF-derived-iPSC were 
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analysed as controls. PCR products were sequenced commercially (GATC Biotech; 
www.gatc-biotech.com) and analysed manually to identify sequence differences 
between the HLHS patient DNA and the one obtained from unaffected control 
(NHDF).  
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